Principia Biopharma
220 E Grand Ave
South San Francisco
California
94080
United States
Tel: 650-416-7700
Website: http://www.principiabio.com/
Email: info@principiabio.com
54 articles about Principia Biopharma
-
Principia Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results
3/10/2020
Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced financial results for the fourth quarter and full year ended December 31, 2019.
-
Principia to Present at 9th Annual SVB Leerink Global Healthcare Conference
2/19/2020
Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced that management will participate in the SVB Leerink Global Healthcare Conference
-
Principia Announces Expansion of its BTK Franchise with PRN473 Topical
1/9/2020
Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced an expansion of its Bruton tyrosine kinase (BTK) franchise with PRN473 Topical.
-
Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated Diseases
1/7/2020
Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, today announced an expansion in the development of rilzabrutinib (PRN1008) into IgG4-Related Disease (RD).
-
Even with the holiday week, there was still some clinical trial news coming out. Here’s a look.
-
Principia Updates PRN1008 Pemphigus Clinical ProgramAccelerated enrollment of company’s Phase 3 pivotal trial anticipating final results in second half of 2021
12/30/2019
Updated anticipated timing for final results in its ongoing pivotal Phase 3 clinical trial of PRN1008 data in patients with pemphigus, as well as complete response rates from its Phase 2 Part B open-label trial.
-
Principia Presents Consistent Positive Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
12/7/2019
Investigational oral BTK inhibitor demonstrates rapid onset and increased treatment responses over time as well as a favorable tolerability profile in 31 patients who have no other treatment options
-
Top 10 Biotech Bay Companies by Revenue
11/18/2019
The companies included on this list are the top ten companies headquartered in Biotech Bay based on 2018 revenue. -
Principia to Present at the Stifel Healthcare Conference 2019
11/13/2019
Principia Biopharma Inc. announced that management will participate in the Stifel Healthcare Conference on Tuesday, November 19, 2019, at 11:30 am EST in the Garrison Room at the Lotte New York Palace Hotel.
-
Principia Biopharma Reports Third Quarter Financial Results
11/5/2019
Principia Biopharma Inc., a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, announced financial results for the third quarter ended September 30, 2019.
-
Principia Announces Pricing of Public Offering of Common Stock
10/16/2019
Principia Biopharma Inc. announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock at a price to the public of $28.00 per share.
-
Principia Announces Proposed Public Offering of Common Stock
10/15/2019
Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated diseases, today announced that it has commenced an underwritten public offering of $125 million of its common stock.
-
Principia Announces Positive Preliminary Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 TrialPreliminary results from trial have been accepted as an oral presentation at upcoming American Society of Hematology Annual Meeting
10/15/2019
Principia Biopharma Inc. announced positive preliminary data from an ongoing Phase 1/2 trial of its investigational treatment, PRN1008, in a highly treatment-resistant and refractory patient population with immune thrombocytopenia Further updated data from the trial will be presented at an oral scientific session at the 61st American Society of Hematology Annual Meeting in December
-
Principia Announces Positive Preliminary Data of PRN1008 from its Ongoing Phase 2 Part B Trial in Pemphigus
10/10/2019
Principia Biopharma Inc. announced positive preliminary data from its Phase 2 pemphigus, open-label, trial.
-
Principia Biopharma Announces Positive Data from Phase 2 Pemphigus Vulgaris Trial at 2019 American Academy of Dermatology Annual Meeting in Late-Breaking Presentation
3/2/2019
Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced Phase 2 clinical data from the Believe-PV study for PRN1008 as part of the Late-breaking Research: Clinical Trials program at the American Academy of Dermatology (AAD) annual meeting in Washington D.C
-
PRINCIPIA BIOPHARMA ANNOUNCES THE ACCEPTANCE OF DATA FROM PHASE 2 PEMPHIGUS VULGARIS TRIAL AS A LATE-BREAKING PRESENTATION AT 2019 AMERICAN ACADEMY OF DERMATOLOGY MEETING
2/22/2019
Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced that an abstract has been accepted for oral presentation at the Late-Breaking Research during the 2019 American Academy of Dermatology annual meeting in Washington, D.C.
-
SVB Financial Group to Buy Venture Capital Firm Leerink, a Top 10 Underwriter for Biotech IPOs
11/14/2018
Leerink Holdings is the Boston-based parent company of Leerink Partners. Leerink Partners is an investment bank focused on healthcare and life sciences. -
South San Francisco-based Principia Biopharma is looking to become a publicly traded company and is aiming for a $86 million initial public offering. The company filed its prospectus with the U.S. Securities and Exchange Commission on Aug. 17.
-
Principia Confirms Human CNS Exposure and Good Tolerability of Oral BTK Inhibitor PRN2246
7/26/2018
Principia Biopharma Inc. today announced that dosing has been completed for all participants in a Phase 1 clinical trial of PRN2246, a Bruton’s tyrosine kinase (BTK) inhibitor designed to cross the human blood-brain barrier.
-
Principia Biopharma Initiates Clinical Trial for PRN1008 in Patients With Immune Thrombocytopenia Purpura
12/13/2017
Principia also has an on-going clinical program for PRN1008 in patients with pemphigus, another autoimmune disease, where it has seen a promising efficacy and safety profile to date.